Correction: MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis (Oncotarget (2015) 6 (13201-13215) DOI: 10.18632/oncotarget.3915);MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis

Oncotarget

Volumn 6, Issue 15, 2015, Pages 13201-13215

  Xiao, Haibing ^a   Zeng, Jin ^a   Li, Heng ^a   Chen, Ke ^a   Yu, Gan ^a   Hu, Junhui ^a   Tang, Kun ^a   Zhou, Hui ^a   Huang, Qihong ^b   Li, Anping ^b   Li, Yi ^a   Ye, Zhangqun ^a   Wang, Ji ^c   Xu, Hua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WISTAR INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

CcRCC; Metastasis; MiR 1; Proliferation

Indexed keywords

CAPRIN1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MICRORNA 1; TRANSCRIPTION FACTOR SLUG; UNCLASSIFIED DRUG; CAPRIN1 PROTEIN, HUMAN; CELL CYCLE PROTEIN; MICRORNA; MIRN1 MICRORNA, HUMAN; SNAI1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SNAIL;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MALE; METASTASIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; GENETICS; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

CARCINOMA, RENAL CELL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DOWN-REGULATION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTORS;

EID: 84931088590     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.27357     Document Type: Erratum

References (44)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013;63:11-30.
2. Yan BC, Mackinnon AC and Al-Ahmadie HA. Recent developments in the pathology of renal tumors: morphology and molecular characteristics of select entities. Archives of pathology & laboratory medicine. 2009;133:1026-1032.
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
4. Esquela-Kerscher A and Slack FJ. Oncomirs - microRNAs with a role in cancer. Nature reviews Cancer. 2006;6:259-269.
5. Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, Nguyen LT, Hijiya N, Uchida T, Sato F, Mimata H, Seto M and Moriyama M. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. The Journal of pathology. 2008;216:418-427.
6. Hidaka H, Seki N, Yoshino H, Yamasaki T, Yamada Y, Nohata N, Fuse M, Nakagawa M and Enokida H. Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget. 2012;3:44-57.
7. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, Gomella LG, Croce CM and Baffa R. Micro-RNA profiling in kidney and bladder cancers. Urologic oncology. 2007;25:387-392.
8. Jung M, Mollenkopf HJ, Grimm C, Wagner I, Albrecht M, Waller T, Pilarsky C, Johannsen M, Stephan C, Lehrach H, Nietfeld W, Rudel T, Jung K and Kristiansen G. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. Journal of cellular and molecular medicine. 2009;13:3918-3928.
9. Weng L, Wu X, Gao H, Mu B, Li X, Wang JH, Guo C, Jin JM, Chen Z, Covarrubias M, Yuan YC, Weiss LM and Wu H. MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens. The Journal of pathology. 2010;222:41-51.
10. Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S, Liu CG, Volinia S, Croce CM, Schmittgen TD, Ghoshal K and Jacob ST. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 2008;68:5049-5058.
11. Liu YN, Yin JJ, Abou-Kheir W, Hynes PG, Casey OM, Fang L, Yi M, Stephens RM, Seng V, Sheppard-Tillman H, Martin P and Kelly K. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene. 2013;32:296-306.
12. Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, Wang B, Suster S, Jacob ST and Ghoshal K. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. The Journal of biological chemistry. 2008;283:33394-33405.
13. Nohata N, Sone Y, Hanazawa T, Fuse M, Kikkawa N, Yoshino H, Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, Shozu M, Okamoto Y and Seki N. miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget. 2011;2:29-42.
14. Rao PK, Missiaglia E, Shields L, Hyde G, Yuan B, Shepherd CJ, Shipley J and Lodish HF. Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2010;24:3427-3437.
15. Tominaga E, Yuasa K, Shimazaki S and Hijikata T. MicroRNA-1 targets Slug and endows lung cancer A549 cells with epithelial and anti-tumorigenic properties. Experimental cell research. 2013;319:77-88.
16. Zhang D, Li X, Chen C, Li Y, Zhao L, Jing Y, Liu W, Wang X, Zhang Y, Xia H, Chang Y, Gao X, Yan J and Ying H. Attenuation of p38-mediated miR-1/133 expression facilitates myoblast proliferation during the early stage of muscle regeneration. PloS one. 2012;7:e41478.
17. Li L, Sarver AL, Alamgir S and Subramanian S. Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma. Laboratory investigation; a journal of technical methods and pathology. 2012;92:571-583.
18. Leone V, D'Angelo D, Rubio I, de Freitas PM, Federico A, Colamaio M, Pallante P, Medeiros-Neto G and Fusco A. MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1alpha. The Journal of clinical endocrinology and metabolism. 2011;96:E1388-1398.
19. Takaya T, Ono K, Kawamura T, Takanabe R, Kaichi S, Morimoto T, Wada H, Kita T, Shimatsu A and Hasegawa K. MicroRNA-1 and MicroRNA-133 in spontaneous myocardial differentiation of mouse embryonic stem cells. Circulation journal: official journal of the Japanese Circulation Society. 2009;73:1492-1497.
20. Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, Xiao P, Shi H, Wang R, Chen L, Chen S, Du Q, Yang H and Zhang X. miR-141 is A Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014;20:2617-30.
21. Zhang L, Zhang X, Barrisford GW and Olumi AF. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer letters. 2007;251:146-157.
22. He XX, Chang Y, Meng FY, Wang MY, Xie QH, Tang F, Li PY, Song YH and Lin JS. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012;31:3357-3369.
23. Ding J, Huang S, Wu S, Zhao Y, Liang L, Yan M, Ge C, Yao J, Chen T, Wan D, Wang H, Gu J, Yao M, Li J, Tu H and He X. Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nature cell biology. 2010;12:390-399.
24. Li D, Liu X, Lin L, Hou J, Li N, Wang C, Wang P, Zhang Q, Zhang P, Zhou W, Wang Z, Ding G, Zhuang SM, Zheng L, Tao W and Cao X. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. The Journal of biological chemistry. 2011;286:36677-36685.
25. Shu M, Zheng X, Wu S, Lu H, Leng T, Zhu W, Zhou Y, Ou Y, Lin X, Lin Y, Xu D, Zhou Y and Yan G. Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells. Molecular cancer. 2011;10:59.
26. Yu G, Li H, Wang J, Gumireddy K, Li A, Yao W, Tang K, Xiao W, Hu J, Xiao H, Lang B, Ye Z, Huang Q and Xu H. MicroRNA-34a suppresses cell proliferation and metastasis by targeting CD44 in human renal carcinoma cell. The Journal of urology. 2014;192:1229-37.
27. Li H, Yu G, Shi R, Lang B, Chen X, Xia D, Xiao H, Guo X, Guan W, Ye Z, Xiao W and Xu H. Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy. Molecular cancer. 2014;13:8.
28. Chen WS, Leung CM, Pan HW, Hu LY, Li SC, Ho MR and Tsai KW. Silencing of miR-1-1 and miR-133a-2 cluster expression by DNA hypermethylation in colorectal cancer. Oncology reports. 2012;28:1069-1076.
29. Kawakami K, Enokida H, Chiyomaru T, Tatarano S, Yoshino H, Kagara I, Gotanda T, Tachiwada T, Nishiyama K, Nohata N, Seki N and Nakagawa M. The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur J Cancer. 2012;48:827-836.
30. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006;24:1770-1783.
31. Faussillon M, Monnier L, Junien C and Jeanpierre C. Frequent overexpression of cyclin D2/cyclin-dependent kinase 4 in Wilms' tumor. Cancer letters. 2005;221:67-75.
32. Fujimoto T, Anderson K, Jacobsen SE, Nishikawa SI and Nerlov C. Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C/ EBPalpha interaction. The EMBO journal. 2007;26:2361-2370.
33. Matushansky I, Radparvar F and Skoultchi AI. CDK6 blocks differentiation: coupling cell proliferation to the block to differentiation in leukemic cells. Oncogene. 2003;22:4143-4149.
34. Wang B, David MD and Schrader JW. Absence of caprin-1 results in defects in cellular proliferation. Journal of immunology. 2005;175:4274-4282.
35. Wang B, David MD and Schrader JW. Absence of Caprin-1 Results in Defects in Cellular Proliferation. The Journal of Immunology. 2005;175:4274-4282.
36. Kaddar T, Rouault JP, Chien WW, Chebel A, Gadoux M, Salles G, Ffrench M and Magaud JP. Two new miR-16 targets: caprin-1 and HMGA1, proteins implicated in cell proliferation. Biology of the cell / under the auspices of the European Cell Biology Organization. 2009;101:511-524.
37. Baker SJ and Reddy EP. CDK4: A Key Player in the Cell Cycle, Development, and Cancer. Genes & cancer. 2012;3:658-669.
38. Carleton M, Cleary MA and Linsley PS. MicroRNAs and Cell Cycle Regulation. Cell Cycle. 2007;6:2127-2132.
39. Thiery JP, Acloque H, Huang RY and Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell. 2009;139:871-890.
40. Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB, Dorsey TH, Stephens RM, Croce CM and Ambs S. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic acids research. 2012;40:3689-3703.
41. Li H, Wang J, Xiao W, Xia D, Lang B, Yu G, Guo X, Guan W, Wang Z, Hu Z, Liu J, Ye Z and Xu H. Epigenetic alterations of Kruppel-like factor 4 and its tumor suppressor function in renal cell carcinoma. Carcinogenesis. 2013;34:2262-2270.
42. Chen K, Yu G, Gumireddy K, Li A, Yao W, Gao L, Chen S, Hao J, Wang J, Huang Q, Xu H and Ye Z. ZBRK1, a novel tumor suppressor, activates VHL gene transcription through formation of a complex with VHL and p300 in renal cancer. Oncotarget. 2015;6:6959-76.
43. Xiao H, Li H, Yu G, Xiao W, Hu J, Tang K, Zeng J, He W, Zeng G, Ye Z and Xu H. MicroRNA-10b promotes migration and invasion through KLF4 and HOXD10 in human bladder cancer. Oncology reports. 2014;31:1832-1838.
44. Zhao X, Dou W, He L, Liang S, Tie J, Liu C, Li T, Lu Y, Mo P, Shi Y, Wu K, Nie Y and Fan D. MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene. 2013;32:1363-72.